The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If that happens we have no chance to regain
+ Bean
What if there lining up news at same time GHIF can offload.
Sales!!!
Jay : the 5 + 4 letters, I'm tempted to say.
This is a great re entry hopefully a good trade at this level. God I loved this share! But I think it’s worth a punt at this price, going to see how goes, got out of this at 1.40 early this year, never thought I’d get back in at this level when I originally got in at 1.30. Hopefully make some real money this time
Cheers Deerhunter - It didn't take much balls to bale out - if you check my history you will see the reason I got out - albeit berated at he time for having no brains! Either way at 54p I cannot see much downside - apart from back to a 40p low with no news flow - this share is well known for its silence to shareholders and the market in general
@gluefactory , fair play for having the balls to get out when you did , i think you'll get the 12k back with interest!
Taken a 40k purchase at 54p - No news for quite sometime so buying in the hope that the silence has been for a reason - something big about to be announced. Previously sold in Autumn at £1.05 albeit at a £12k loss so hoping to get back that loss with interest
Ive just brought back in.
See what happens
Good Points Inphobe - i'll add those in.
Thanks.
Some amazing test and great products but it all comes down too the 5 letters
Add in CE-mark (and a few other areas, Malaysia and SA if I recall for completeness) on 1 there Stephen11. (And CE for HCV & AIHL)
Seems if UNICEF supply site is to be believed there's an LTA lurking with UNICEF on the HCV too?
3 products in PHE (From RNS "All of genedrive's currently available and CE marked products fall within the framework agreement: Genedrive® 96 SARS-CoV-2 Kit, Genedrive® HCV ID Kit, Genedrive® MT-RNR1 ID Kit")
As you say, healthy ratio plus current low mcap
These feel good posts don’t change anything unfortunately, seen them for months now.
It’s a hard hold right now but average down if possible , I’d say wait a few more days at least as this is going way down
This share is reminiscent of the game show "TIPPING POINT". Anyone of the deals, some, or all could come to fruition and create an AVALANCHE of cash. Maybe some don't have the patience to delay gratification? Make up your own mind.
1/ Genedrive 96-SARS-COV-2kit
- Huge worldwide potential
- 97.6% sensitivity and 98.2% specificity, compared to poor lateral flow test performance (sometimes as high as 50% false positives)
- Agreement with BC started 28th Jan 2021. Sales will materialise, though lead times and sales cycles should be considered
- Regulatory approval for Thailand and Senegal
- FDA frustrating, though the pace of approvals is accelerating
2/ Pathogen Detection (Bioplex): supplier to US military
- Development contract worth owner 10 million
- 500 kits over 3 years
- Partnership with MountainHorse: this will help develop a broader customer base
3/ Antibiotic induced hearing loss test
- World first
- Worldwide neo-natal hearing loss market worth 35-50 million annually (very niche market)
- Launch summer 2021 to UK and Ireland. Worldwide potential thereafter
- 100% accuracy in testing
4/ World first decentralised qualitative molecular HCV test
- Routes to market impacted by COVID
- Good medium to long-term potential
- High efficacy in a recent peer reviewed study
5/ Listed on the PHE chosen contractors list
- Potential for a share of the 3 billion budgeted future spend
6/ Regulatory approval for Indian market
- High test efficacy; 100% specificity and 100% sensitivity
- Access to a market equivalent to 17.7% of the total world population
- Divoc already in place
- Other contacts also being sourced
In Development
1/ Genedrive Saliva Test
- 15/20 minute rapid turnover
- Target market: schools/offices/travel etc.
- High accuracy unlike lateral flow tests
2/ Point of care test for tuberculosis
- On hold due to COVID, though good future potential for 2022/2023.
Other important points
- Healthy cash to burn ratio
- High stock levels to fulfil orders
- European ministry of health opportunity. Potential for a low double digit millions of pound order to be delivered in a short period of time
Good luck all